<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071511</url>
  </required_header>
  <id_info>
    <org_study_id>PV4286</org_study_id>
    <nct_id>NCT02071511</nct_id>
  </id_info>
  <brief_title>Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation</brief_title>
  <acronym>ARDEVAT</acronym>
  <official_title>Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis:&#xD;
&#xD;
      With optimal medical therapy and repeated ablations, an additional renal denervation may have&#xD;
      protective effects in terms of vegetative intrinsic activity and lead to a significant&#xD;
      reduction in VT Burdens.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Multicenter, randomized, prospective, single-blind clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study protocol:&#xD;
&#xD;
      Catheter ablation of ventricular tachycardia versus combined catheter ablation of ventricular&#xD;
      tachycardia and renal denervation.&#xD;
&#xD;
      A total of 50 patients with ventricular tachycardia treated with ICD shocks or ATP will be&#xD;
      enrolled in this study. The randomization in the study is done before ablation.&#xD;
&#xD;
      For the ablation, an arterial access is required in both groups. During a 30 minutes waiting&#xD;
      time which will apply to both groups, renal denervation will be performed.&#xD;
&#xD;
      In this period of time operators and staff will be blinded for the procedure, thereby they&#xD;
      won't know if the patients will receive a renal denervation, in that way the investigators&#xD;
      are avoiding a bias of future treatment of the patients.&#xD;
&#xD;
      Follow up and repeat procedures:&#xD;
&#xD;
      All Patients will be followed for a period of 3, 6, 9, 12 and 18 months after the procedure.&#xD;
&#xD;
      Regular visits are done in the investigators office. The visit will include ICD&#xD;
      Interrogation, VT documentation in ICD Holter, 24-hour Holter ECG or Tele-ECGs,&#xD;
      echocardiography.&#xD;
&#xD;
      Re- VT ablations are allowed at any time. In case of renal artery stenosis, denervation will&#xD;
      not be performed. Drug therapy can be continued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    results of the SYMPLICITY HTN 3 trial&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with adverse events such as recurrens of Ventricular Tachycardias or necessary Intracardiac shocks during 24 months follow up</measure>
    <time_frame>24 months</time_frame>
    <description>Number of Patients with adverse events such as recurrens of Ventricular</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Ventricular extrasystoles and non-sustained Ventricular Tachycardias compared to the time prior to ablation during 24 months follow up</measure>
    <time_frame>24 months</time_frame>
    <description>Number of Patients with Ventricular extrasystoles and non-sustained Ventricular Tachycardias compared to the time prior to ablation during 24 months follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of periprocedural complications</measure>
    <time_frame>24 months</time_frame>
    <description>Number of periprocedural complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ablation of ventricular arrhythmias</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ablation of ventricular arrhythmias + renal denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of ventricular arrhythmias</intervention_name>
    <description>control group: Ablation of ventricular arrhythmias</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of ventricular arrhythmias + renal denervation</intervention_name>
    <description>Intervention group: Ablation of ventricular arrhythmias + renal denervation</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Ischemic cardiomyopathy&#xD;
&#xD;
          -  NYHA II-III&#xD;
&#xD;
          -  Recurrent ventricular tachycardia, ICD interventions (shock or ATP)&#xD;
&#xD;
          -  Obtained written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Previous VT ablation&#xD;
&#xD;
          -  NYHA IV&#xD;
&#xD;
          -  Cardiopulmonary decompensation within the last 4 weeks&#xD;
&#xD;
          -  Pregnant women or women of childbearing potential without a negative pregnancy test&#xD;
             within 48 hours prior to treatment&#xD;
&#xD;
          -  History of hemorrhagic diathesis or other coagulopathies&#xD;
&#xD;
          -  Contraindication for oral anticoagulation&#xD;
&#xD;
          -  Hyper- or hypothyroidism&#xD;
&#xD;
          -  Drug or chronic alcohol abuse&#xD;
&#xD;
          -  Has any condition that would make participation not be in the best interest of the&#xD;
             subject&#xD;
&#xD;
          -  Incompliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>April 28, 2019</last_update_submitted>
  <last_update_submitted_qc>April 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

